POS1259 FAVOURABLE SHORT-TERM COURSE OF COVID-19 IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER USING BIOLOGIC AGENTS
Authors: N. Aliyeva, B. Ç. Yalçin Dulundu, S. Amikishiyev, S. Aghamuradov, M. Bektaş, B. Ince, N. Koca, Y. Yalçinkaya, B. Artim-Esen, M. Inanc, A. Gül
Journal: Annals of the Rheumatic Diseases (2021)

Background: COVID-19 runs a variable course resulting in acute respiratory distress syndrome and death in a subset of patients. The entry of SARS-CoV-2 into the cell stimulates innate immunity including NLRP3 inflammasome and lead to development of adaptive immunity later. Hyperinflammatory response with the release of proinflammatory cytokines including IL-1β and IL-6 results in cytokine storm in some patients with a worse outcome. Colchicine acts on NLRP3 inflammasome and inhibits and IL-1 mediated inflammatory attacks in gout and familial Mediterranean fever (FMF) patients. Patients with inadequate response to colchicine may benefit from anti-IL-1 biologic agents such as anakinra and canakinumab. Recently, favourable effects of anakinra have been observed in COVID-19 patients with findings of cytokine storm. Objectives: We aimed to evaluate the impact of COVID-19 among refractory FMF patients followed-up in tertiary referral with the treatment of biologic agents and also document the course of COVID-19 in these patients. Methods: We searched out database of FMF patients to identify those using biologic agents (anti-IL-1, anti-IL-6 or anti-TNF) for colchicine-refractory FMF. We interviewed the patients using a standard questionnaire by phone call for symptomatic COVID-19 and evaluated those patients who described findings of COVID-19 further by their hospital records or inviting them to the hospital for additional investigations. Results: We identified 183 patients and contacted 106 of them by phone in May-October 2020. A history of symptomatic COVID-19 was documented in 7 FMF patients who were on a biologic agent. Six were on anti-IL-1 and one was on anti-TNF, and one of the patients was not taking his biologic agents for 1 year. All of 7 patients had a favourable outcome. All but 1 patient followed at home and none of them developed findings of cytokine storm, thromboembolism and secondary bacterial infection. Hospitalized patient did not require intensive care unit (ICU) support or mechanical ventilation, and he was not given additional anti-inflammatory medications. Conclusion: This series of refractory FMF patients with potentially higher inflammatory characteristics showed COVID-19 did not result in a worse outcome in those patients during the first phase of the pandemic, and none developed findings of cytokine storm. Observations in these patients supports further that biologic agents blocking IL-1 and possibly TNF may contribute to the uneventful course of COVID-19 by preventing the development of hyperinflammatory response. Data collection from a larger group of patients, especially those with amyloidosis, will clarify the protective effects of colchicine and contribution of anti-IL-1 treatments on the favourable disease course during the second phase of the pandemic. Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Age (years) 45 48 39 53 32 37 31 MEFV variants Unknown M694V /M680I Unknown M694V/ M694V M694V/ M694V M694V/ M694V M694V/ M694V Amyloidosis No No No No No No No Biologic agents Anakinra 100 mg/day Not takenfor 1 year Adalimu-mab Canakinumab 150 mg/month Anakinra 100 mg/day Canakinumab 150 mg/month Anakinra 100 mg/day Prednisone (mg/day) 5 No No No No No No Colchicine (mg/day) 2 1,5 1,5 1,5 1,5 2,0 2,0 RT-PCR positivity Yes Yes Yes Yes Yes Yes Yes Chest CT signs Yes Yes Not done Not done Not done Not done Not done Hospitalisation No No No Yes No No No Antiviral therapy Oseltamivir Oseltamivir No Favipravir Favipravir Favipravir Favipravir HCQ use Yes Yes Yes Yes No No No New FMF attack during COVID-19 No No No No No No No Disclosure of Interests: None declared